Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Immunologic Deficiency Syndromes 1IgA Deficiency 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × B-Cell Activating Factor × Clear all
NCT00024934 2016-09-22

B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled

Immunologic Deficiency Syndromes, Neoplasms, IgA Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡